iSERA Lifesciences Ltd vs Tata Consultancy Services Limited
A side-by-side comparison of iSERA Lifesciences Ltd (COVIDHLTD) and Tata Consultancy Services Limited (TCS) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Tata Consultancy Services Limited leads COVIDHLTD vs TCS on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation13
- Profitability22
- Growth· not comparable—
- Size & financial health04
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
TCS takes 3/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
EvenHow efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
TCS takes 4/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Promoter holding has increased by 55.1% over last quarter."]
- − ["Stock is trading at 14.7 times its book value", "Company has high debtors of 337 days.", "Promoter holding has decreased over last 3 years: -41.4%"]
- + ["Company has a good return on equity (ROE) track record: 3 Years ROE 50.9%", "Company has been maintaining a healthy dividend payout of 80.5%"]
- − ["Stock is trading at 8.31 times its book value"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.